Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

at a price of $2.87.

Based on the Company's currently planned expenditures and assuming no unanticipated expenses, the Company estimates its cash reserves will be sufficient to meet anticipated cash needs for working capital and capital expenditures for the next twelve months. The Company has no external sources of liquidity such as bank lines of credit. The Company will require future additional financing to carry out its business plan. The market for both debt and equity financings for companies such as Helix has always been challenging, and the global economic downturn and credit crisis have added further challenges. There can be no assurance that a financing, whether debt or equity, will be available on acceptable terms or at all.

The Company's consolidated fiscal 2009, 2008, and 2007 financial statements are summarized below.

    Consolidated Statements of Operations
    (thousand $, except for per share data)

                                              2009     2008     2007
                                              ----     ----     ----
    Revenue:
      Product revenue                        3,244    2,952    2,764
      License fees & royalties                 597      639      512
      Research and development contracts         -        -      148
                                                --       --      ---
                                             3,841    3,591    3,424

    Expenses:
      Cost of sales                          1,516    1,239    1,139
      Research and development              10,322    5,064    4,116
      Operating, general and admin           3,917    3,948    3,570
      Sales and marketing                      969      809      848
      Amortization of intangibles               12       16      159
      Amortization of capital assets           274      254      287
      Stock-based compensation               1,023       44       47
      Interest income               
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Mandatory takeover offer for ... or the "Company") is pleased to announce the signing ... Marijan Han žeković to acquire his 63.3% holding ... a Croatian listed pharmaceutical business.   Dechra ... to €51.4 million for the entire share capital on ...
(Date:7/31/2015)... , July 31, 2015  Physicians and ... in the biopharmaceutical market. Patients are better informed ... selecting and switching therapies. This shift in power ... marketers, efforts toward patient-focused marketing. As ... marketers have learned it,s important to educate, communicate ...
(Date:7/31/2015)... July 31, 2015  Seeger Weiss LLP is reporting that ... a warning letter to C.R. Bard, the manufacturer of ... strides to correct violations the agency found at two of ... after the FDA cited them during Inspectional Observations that occurred ... Tempe, AZ , location and on October ...
Breaking Medicine Technology:Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... ADDISON, Texas, March 11, 2011 U LURUInc.(NYSE ... the development of a portfolio of wound management and oral ... NYSE Amex LLC (the "Exchange") advising ULURU that it is ... continued listing standards under Section 1003 of the Exchange,s Company ...
... (Nasdaq: NVAX ), a clinical-stage vaccine company, announced ... be presenting at the ROTH 23rd Annual OC Growth Stock ... at The Ritz Carlton, Laguna Niguel, CA.  A live audio-only ... Company website at www.novavax.com under Investors/Events, and a ...
Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... They know ... Providence St. Vincent Medical Center offers some of the best care in the ... neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the country. ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles ... need. Most people know that general health emergencies, such as broken arms or a ... people know where to turn to during a dental emergency. This is important, because ...
(Date:8/3/2015)... , ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: ... is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 ... webcast and subsequent archived replay of the Company’s presentation may be accessed via the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... research suggests that the patients who undergo surgery to ... later developing pancreatic cancer. The investigators base their findings ... operation known as gastrectomy to remove their ulcers.// ... the stomach or a portion of the small intestine, ...
... has sex and any subsequent risk of birth defects such ... of sex might increase the risk of birth defects in ... and gynecology at Baylor College of Medicine in Houston told ... known causes of birth defects in lower animals. ...
... The government approved a long-awaited treatment for lymphoma - ... radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin becomes ... US. // ,It's a new approach, adding ... CD20 found on lymphoma cells. The antibodies attach to ...
... group have developed an efficient method of identifying strains ... diseases such as meningococcal disease. The Cooperative ... Technology (QUT) has taken advantage of two new technologies// ... recently - DNA chip technology and comparative gene sequence ...
... which could make gene therapy powerful. The advance which is ... the modified genes to slip right into the cell nucleus.A ... an entire human.// ,This means that the DNA molecule ... smuggle or slip their modified DNA strands into the cells ...
... to a new study, filtering out the antibodies that can ... live donor transplants. Many patients need a kidney transplant but ... Body organs, from dead bodies, are in short supply, and ... must be of a compatible blood group. ,But ...
Cached Medicine News:Health News:Ulcer Surgery connected to danger of Pancreatic Cancer 2Health News:Identifying bacteria made amiable 2
... Plus Dodeca cell accommodates up to 12 ... first-dimension runs in the PROTEAN IEF system, ... format. The PROTEAN Plus Dodeca cell's cooling ... electrodes, allow consistent, high-resolution results. The handcasting ...
... The PROTEAN Plus Dodeca cell accommodates up ... capacity of first-dimension runs in the PROTEAN ... a convenient format. The PROTEAN Plus Dodeca ... its plate electrodes, allow consistent, high-resolution results. ...
... gels run in the specially designed E-Base™ ... power supply in one device. The daughter ... and to other daughter E-Base™ platforms for ... E-Gel® 96 or E-Gel® 48 gels. Note: ...
... E-Gel® 48 gels run in the ... combine the base and power supply ... E-Base™ power supply contains an electrical ... to an electrical outlet and is ...
Medicine Products: